Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders-Reference-Cited by-同舟云学术

Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders

Published:2023-11-03 Issue:21 Volume:7 Page:6767-6770
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Fillmore Nathanael R.¹²³^ORCID,La Jennifer¹²,Wu Julie Tsu-Yu⁴⁵^ORCID,Corrigan June K.¹,Branch-Elliman Westyn¹²^ORCID,Monach Paul¹²,Brophy Mary T.¹⁶,Do Nhan V.¹⁶^ORCID,Munshi Nikhil C.¹²³

Affiliation:

1. 1VA Boston Healthcare System, Boston, MA

2. 2Department of Medicine, Harvard Medical School, Boston, MA

3. 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

4. 4VA Palo Alto Healthcare System, Palo Alto, CA

5. 5Department of Medicine, Stanford University, Stanford, CA

6. 6Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/7/21/6767/2089245/blooda_adv-2023-011063-main.pdf

Reference12 articles.

1. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network;Ludwig;Lancet Haematol,2021

2. Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders;La;Blood,2022

3. Association of COVID-19 vaccination with SARS-CoV-2 infection in patients with cancer: a US Nationwide Veterans Affairs study;Wu;JAMA Oncol,2022

4. With equal access, African American patients have superior survival compared to White patients with multiple myeloma: a VA study;Fillmore;Blood,2019

5. Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in multiple myeloma patients;Henriquez;Blood,2022